BHCM
BDSX icon

Brevan Howard Capital Management’s Biodesix BDSX Stock Holding History

Brevan Howard Capital Management’s Portfolio BDSX Stock Details BDSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-526
Closed -$15.1K – 1071
2024
Q1 		$15.1K Buy
+526
New +$18K ﹤0.01% 960

Other funds holding BDSX

TAM
Telemark Asset Management Boston, Massachusetts $1.08B AUM 70.88% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Brevan Howard Capital Management's BDSX Position: Q2 2024 in Review

Brevan Howard Capital Management sold out of Biodesix (BDSX) in Q2 2024, closing a stake of 526 shares — an estimated $15.1K sold.

Brevan Howard Capital Management first reported a position in BDSX in Q1 2024 and held it in 1 quarter. The position peaked at $15.1K in Q1 2024. 46 funds tracked by Wall St. Rank hold BDSX as of Q2 2024.

  • Brevan Howard Capital Management reported no remaining Biodesix position as of Q2 2024 after selling out during the quarter.
  • Brevan Howard Capital Management sold 526 Biodesix shares in Q2 2024, an estimated $15.1K.
  • Brevan Howard Capital Management first reported a position in Biodesix in Q1 2024 and held it in 1 quarter.
  • Brevan Howard Capital Management's Biodesix position peaked at $15.1K in Q1 2024.
  • 46 funds tracked by Wall St. Rank held Biodesix as of Q2 2024.

Based on Brevan Howard Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.